Brevibloc 100 mg
Brevibloc 100 mg is a medicine authorised by Swissmedic under authorisation number 49576. The authorisation holder is Baxter AG. The medicinal product code is Synthetic medicines and the dispensing category is B: Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly. First authorisation was granted on 20 March 1990 and the authorisation is valid without a time limit. ATC code C07AB09 places the medicine in the group Beta blocking agents.
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 2 | Brevibloc 100 mg, Injektionslösung | B | 19 June 1991 |
| 3 | Brevibloc 2,5 g/250 ml, Infusionslösung | B | 30 September 2002 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 21 | 5 | Durchstechflasche(n) | C07AB09 | 02.03.0. | B |
| 48 | 250 | ml | C07AB09 | 02.03.0. | B |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is Brevibloc 100 mg authorised in Switzerland?
Yes. Brevibloc 100 mg is authorised by Swissmedic under authorisation number 49576, data as of 01 September 2026. The authorisation is valid without a time limit.
Which dispensing category does Brevibloc 100 mg have?
Brevibloc 100 mg is in dispensing category B. Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly.
Who is the authorisation holder of Brevibloc 100 mg?
The authorisation holder is Baxter AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.